INTRODUCTION
============

More than 75% of bladder cancer is classified as nonmuscle-invasive bladder cancer (NMIBC), which is confined to the mucosal and stroma or lamina propria ([@B1][@B2]). The tumor recurrence of NMIBC varies from 30% to 80%; and 1% to 45% is known to progress into muscle invasive bladder cancer within 5 yr ([@B1][@B2]). Therefore, NMIBC is considered to be a heterogeneous disease, some of which might show the risk of progression to muscle invasion applicable for cystectomy during follow-up. However, there are no available clinical and pathological factors and is substantial need to find new predictive markers that indicate tumor recurrence or progression to effective treatment of the NMIBC patients.

During recent years, some literature described clinical and molecular predictive factors as accurate prognostic assessment for NMIBC patients ([@B3][@B4][@B5][@B6]). European Organization for Research and Treatment of Cancer (EORTC) proposed an NMIBC calculator that could predict the short- and long-term risks of recurrence and progression based on six clinicopathologic variables including grade, stage, concomitant carcinoma in situ (CIS), multiplicity, tumor size, and previous recurrence rate ([@B2][@B6]). Regarding molecular predictive factors, there are many studies that investigate various markers such as p53, Cyclin D1, FGFR-3, Ki-67, Cathepsin E, and maspin as significant predictors of recurrence or progression ([@B4][@B5][@B7][@B8][@B9]). However, overestimated risks of both recurrence and progression were reported when applying the EORTC tables to BCG-treated patients ([@B9]) and no molecular markers are currently in clinical use as predictive or prognostic marker in NMIBC.

The human epidermal growth factor receptor 2 (HER2) expression has been extensively investigated as a target therapy and is known to be a useful prognostic and therapeutic marker in breast cancer and advanced gastric cancer ([@B10][@B11]). HER2 is a 185-kDa transmembrane tyrosine kinase receptor of epidermal growth factor receptor family located on chromosome 17q21 and its intrinsic tyrosine kinase activity involves cell proliferation and survival via the RAS-MARK pathway ([@B10][@B11][@B12]). There have been several studies that elaborated on HER2 status in bladder cancers ([@B12][@B13][@B14][@B15]). However, HER2 status in bladder cancer has been reported to vary from 9% to 80% in regards to protein overexpression and 0% to 32% regarding gene amplification of *HER2* ([@B4][@B12][@B13][@B14][@B15]). Therefore, the predictive value of HER2 status in bladder cancer remains controversial. Moreover, there are only a few studies of HER2 status in NMIBC ([@B14][@B15]).

NMIBC is approximately composed of 70% pTa, 20% pT1 and 10% CIS ([@B1][@B2]). Although tumor substaging still remains an issue of controversy, many publications have shown substaging of pT1 tumors correlates with clinical outcome such as progression free time, recurrent free time or disease specific survival ([@B3][@B15][@B16][@B17]). Hence, the aim of this study was to identify the potential impact on the clinical outcome of tumor substaging and HER2 status in NMIBC to verify their prognostic and therapeutic utility.

MATERIALS AND METHODS
=====================

Case selection
--------------

A retrospective study was conducted on patients who underwent transurethral resection (TUR) of bladder tumor and were subsequently diagnosed as NMIBCs between 1998 and 2012 at the Departments of Pathology, Asan Medical Center Seoul, Korea. It comprised of 300 patients who were diagnosed as pTa or pT1 papillary urothelial tumors based on primary TUR specimens, according to the 7th edition American Joint Committee on Cancer TNM system ([@B18]).

All histological sections were reviewed again and graded as papillary urothelial neoplasm of low malignant potential (LMP), low grade and high grade papillary urothelial carcinomas according to 2004 WHO classification ([@B19]). Tumor substaging was divided into four categories as follows; pTa (no invasion into the stroma), pT1a (invasion into the stroma but not to muscularis mucosa (MM), pT1b (invasion into MM but not beyond MM), pT1c (invasion beyond the MM but not to muscularis propria). pT1 tumors samples from TUR specimens that contained proper muscle were incorporated in this study and their substaging rate was 81.4% (144/177 pT1 tumors). Concomitant CIS and lymphovascular invasion were also included during review. Clinicopathologic data including age, sex, tumor size, and multifocality were collected from medical reports. After re-evaluating specimens and reviewing the hospital records, 141 NMIBCs were deemed fit for the final study because specimens were missing or not applicable for tissue microarray (TMA) construction and HER2 assessment as well as insufficient clinicopathologic information in the hospital records.

Recurrence was defined as occurrence of a new tumor confirmed by biopsy after three months of the first TUR of bladder tumor during follow-up. Progression was defined as recurrence confirmed by biopsy showing invasion into the muscularis propriae or more or distant metastasis, and or death due to the disease during follow-up.

Construction of tissue microarray
---------------------------------

TMAs were constructed using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Three randomly representative 2 mm cores from the circled cancer were obtained from the most representative cancer areas of formalin-fixed paraffin-embedded tissue blocks and were arranged in TMA blocks. Hematoxylin and eosin staining of the TMA sections was performed for tissue confirmation.

Immunohistochemistry
--------------------

TMAs paraffin blocks were sectioned into 4 µm slices, deparaffinized, and antigens demasked in EDTA buffer, pH 8.4. HER2 immunohistochemistry (IHC) was performed using PATHWAY anti-HER2/neu (4B5; rabbit monoclonal; pre-dilution; Ventana Medical Systems, Tucson, AZ, USA) antibody and ultraView Universal DAB kit (Ventana Medical Systems) on an automatic immunostainer (BenchMark XT, Ventana Medical Systems), according to the manufacturer\'s instructions. Primary antibody omission was used for the negative control and breast cancer previously confirmed by HER2-IHC showing 3+ immunopositivity was used for positive control. IHC scoring was independently performed by two pathologists without prior knowledge of clinicopathological information or molecular results obtained via other methods. The scoring was first semiquantitatively analyzed and grouped into 4 categories as follows: 0, no staining; 1+, faint/barely partial membrane staining less than 50% of tumor area; 2+, variable weak-to-moderate complete membrane staining in ≥50% of tumor area; 3+, strong complete membrane staining in all tumor area. The two pathologists completely agreed on all the IHC scoring and IHC 2+ and 3+ were considered to indicate HER2-IHC positive group for statistical reason.

Dual-color silver in-situ hybridization
---------------------------------------

Bright-field dual-color in-situ hybridization (SISH) analysis was performed on TMAs of NMIBCs using the automatic SISH staining device (BenchMark XT, Ventana Medical Systems), according to the manufacturer\'s protocols for INFORM HER2 DNA and INFORM Chromosome 17 (CEP17) probes (Ventana Medical Systems). *HER2*/CEP17 SISH signals were counted according to the interpretive guideline for Ventana INFORM *HER2* DNA probe staining of gastric cancer cells (Ventana Medical Systems) ([@B11]). Tumor cells were scanned for hot spots by using 20× or 40× objectives, and the area with the highest signals was selected. The signals were counted in 20 nonoverlapping tumor cell nuclei from each case using 60× or 100× objectives by two pathologists who were blinded to *HER2* status by other detection methods and clinical information. Small or large clusters were counted as 8 signals and 16 signals, respectively. *HER2* gene amplification was defined as a HER2/CEP17 ratio of ≥2.0 in 20 tumor nuclei. The equivocal cases (ratio: 1.8 to 2.2) were recounted in at least 20 non-overlapping nuclei of different tumor cells at a second target area. Normal HER2 signals (1 to 2 copies per cell) are used as internal positive controls for each case as well as breast cancer tissue previously confirmed by 3+ *HER2* gene amplification.

Statistical analysis
--------------------

The chi-square or Fisher exact test was used to evaluate the stastistical significance of the associations between clinicopathologic parameters. Survival analysis was performed using the Kaplan-Meier method and the significance of differences in survival between the groups was determined using the log-rank test. Multivariate analysis was done to identify variables with independent prognostic relevance using the Cox proportional hazard model. A *P* value of \<0.05 (two-tailed) was used to establish statistical significance. All statistical analyses were conducted using SPSS v. 19.0 (SPSS Inc., Chicago, IL, USA) and dBSTAT v. 5 (dBSTAT Co., Chuncheon, Korea).

Ethics statement
----------------

This study was approved by the institutional review boards of Asan Medical Center (2013-107). Informed consents were waived by the board.

RESULTS
=======

The clinicopathological characteristics of the 141 patients with NMIBC are summarized in [Table 1](#T1){ref-type="table"}. The patients included 122 men (86.3%) and 19 women (13.5%). The mean age of the patients was 68.9 yr (range 20-93 yr). Mean follow duration was 73.3 months (range 3.9-187.9 months). Tumor recurrence and progression were found in 68 (48.2%) and 23 (16.3%) patients during follow-up. 3 cm or more sized tumor was found in 60 (42.6%); and 2 or more of multifocality was found in 66 cases (46.8%). Concomitant CIS was noted in 31 (22%) cases and lymphovascular invasion was present in 3 (2.1%). Tumors were graded to LMP in 14 (9.9%), low grade in 59 (41.8%), and high grade in 68 (48.2%). Pathologic stage consisted of pTa in 65 (46.1%) and pT1 in 76 (53.9%). Substaging of pT1 was made as follows; pT1a in 50, pT1b in 9, and pT1c in 17 ([Table 1](#T1){ref-type="table"}).

HER2 protein expression was semiquantatively scored to 0 in 127 (90.1%), 1 in 8 (5.7%), 2 in 3 (2.1%), and 3 in 3 (2.1%) cases, respectively. Score 2+ and 3+ were considered to indicate HER2-IHC positive in 6 of all 141 NMIBCs (4.3%) ([Fig. 1 A-D](#F1){ref-type="fig"}), one of which is pTa tumor and 5 of which is pT1 tumors (6.6% of 76 pT1 tumors). All HER2-IHC positives were high grade NMIBC and accounted for 8.8% (6/68) of high grade NMIBC and 8.9% (5/56) of high grade pT1 tumors ([Table 2](#T2){ref-type="table"}). *HER2* gene amplification was observed in 4 of all 141 NMIBC (2.8%), all of which were pT1 tumors (5.3%, 4/76 pT1 tumors) and high grade NMIBC (5.9%, 4/68 high grade tumors) ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}) ([Fig. 2A, B](#F2){ref-type="fig"}). *HER2* gene amplification was 7.1% (4/56) of high grade pT1 tumors ([Table 2](#T2){ref-type="table"})

Substaging was significantly associated with tumor grade (*P*\<0.001), concomitant CIS (*P*=0.005), HER2 protein expression (*P*=0.038), and *HER2* gene amplification (*P*=0.002) ([Table 2](#T2){ref-type="table"}). Substaging is also associated with tumor progression (*P*\<0.001) but not in tumor recurrence (*P*=0.993) ([Table 2](#T2){ref-type="table"}).

Tumor grade correlated with concomitant CIS (*P*\<0.001), HER2 protein expression (*P*=0.035), and tumor progression (*P*\<0.001) ([Table 3](#T3){ref-type="table"}). HER2-IHC positive was significantly associated with lymphovascular invasion (*P*=0.004) and all 6 HER2-IHC positive showed tumor progression (*P*\<0.001) ([Table 3](#T3){ref-type="table"}). A firm correlation was observed between HER2 protein expression by immunohistochemistry and gene amplification by SISH (*P*\<0.001). Two HER2-IHC score 2+ cases had absence of *HER2* gene amplification. *HER2*-SISH correlated with lymphovascular invasion (*P*=0.002) and tumor progression (*P*=0.001) ([Table 3](#T3){ref-type="table"}). There is no association of age, sex, tumor size and multifocality with other clinicopathologic parameters.

The average period until the first recurrence was 44.4 months (range, 3.2 to 180.4 months) ([Table 4](#T4){ref-type="table"}). Univariate analysis demonstrated that tumor size and HER2-IHC positive significantly correlated with recurrence-free survival (*P*=0.042, *P*\<0.001, respectively) ([Fig. 3A and B](#F3){ref-type="fig"}). Only HER2-IHC positive NMIBC showed shorter recurrence time with multivariate analysis (*P*=0.019) ([Table 4](#T4){ref-type="table"}).

The average period until the first tumor progression was 69.9 months (range, 3.4 to 180.4 months) ([Table 4](#T4){ref-type="table"}). Substage, multifocality, tumor grade, lymphovascular invasion, HER2 protein expression and gene amplification correlated with progression-free survival (*P*\<0.001, *P*=0.041, *P*\<0.001, *P*\<0.001, *P*\<0.001, *P*\<0.001, respectively) by univariate analysis ([Table 4](#T4){ref-type="table"}) ([Fig. 4A-D](#F4){ref-type="fig"}). Multivariate analysis further demonstrated that substaging, HER2-IHC and *HER2*-SISH were an independent predictive factor of tumor progression for patients with NMIBC (*P*\<0.001, *P*\<0.001, *P*=0.031, respectively) ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

The therapeutic guidelines for NMIBC remain controversial; and conservative management may allow tumor to progress to muscle invasion, which requires cystectomy ([@B1][@B2]). The pathologic stage assessed by the severity of invasion depth is one of the most important prognostic predictors of NMIBC ([@B3][@B16]). Several literatures focusing on clinical significance of substaging pT1 tumors have been published, and their results still remain controversial ([@B3][@B16][@B17]). However, the necessity of substaging was further highlighted in several recent articles which showed strong correlation between progression free survival or overall survival and substaging in pT1 tumors ([@B3][@B16][@B17]). In the current study, the authors reached a consensus to conduct substaging, which yielded meaningful results in establishing the method as a significant prognostic predictor in NMIBC. In addition, higher substage was closely linked to higher tumor grade and greater likelihood of concomitant CIS. Hence, substaging could be recommended to be included in clinical therapeutic guideline for NMIBC.

However, several challenges in substaging have hindered its adoption in clinical guidelines for NMIBC management ([@B16][@B17][@B20]). First, the substaging rate of pT1 tumors varied from 58% to 100% in the literature ([@B17][@B20]) and was 81.4% in our study. We only utilized samples that contained proper muscle tissue for pT1 cases because the incidence of understaging is reported to be 14% when proper muscle tissue is present, while when proper muscle tissue is absent, the incidence is 49% ([@B20]). One persistent problem is low tissue quality, which is caused by damaged TUR specimen and unclear presence of muscularis mucosae. Moreover, there is lack of consensus among pathologists regarding substaging methodology and interobserver variability of its interpretation. In addition to the substaging method covered in this study, several studies have laid out different methods of substaging, which also showed good correlation with outcome ([@B16][@B17][@B20]). Brimo et al. ([@B16]) illustrated the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion for substaging. Hu et al. ([@B17]) measured the dimension of invasive component in pT1 urothelial carcinoma in TUR specimens. Their respective methods showed strong correlation with progression free survival or recurrent free survival. Therefore, further studies will be needed to come to a consensus on methodology and interpretation criteria of substaging.

Recently, there have been a number of articles which noted HER2 overexpression or amplification in many cancers, and these reports led to targeted therapy using trastuzumab ([@B10][@B11][@B21]). As widely known, the therapy is currently used worldwide for treating breast and gastric cancers ([@B10][@B11]). There are well established diagnostic guidelines that identify HER2 positive breast and gastric cancers according to either the ASCO/CAP or ToGA scoring schemes ([@B10][@B11]). Whereas HER2-IHC score 3+ is considered to be HER2 protein overexpression, HER2-IHC score 2+ should be confirmed using ISH by either SISH or fluorescent ISH (FISH) as HER2 positive for both breast and gastric cancers ([@B10]). *HER2*-SISH is known to be more useful method than *HER2*-FISH in a clinical setting as it is fully automated and viewable by bright-field microscopy ([@B22]).

The prognostic values of HER2 expression in bladder cancer have remained unclear due to inconsistent results ([@B4][@B12][@B23]). The figures previously reported in the literature showed a wide range from 9.2% to 85% HER2 expression in bladder cancers ([@B4][@B12][@B13][@B14][@B15]). One reason for this variation is the fact that studies used bladder cancer samples with a varying degree of tumor stages and histological grades. Another reason could be attributed to technical limitations in IHC, and also the fact that there were no clear guidelines for assessing HER2 status for bladder cancer ([@B4][@B12]). Nevertheless, the most recent papers have presented HER2 overexpression was significantly associated with poor clinicopathological factors including lymph node metastasis and poor prognosis in bladder cancer ([@B12][@B13][@B24]). *HER2* gene amplification was also frequently found in the micropapillary variant of urothelial carcinoma of the bladder, which is a rare but aggressive subtype ([@B25]).

Lae et al. ([@B12]) investigated HER2 status using very well calibrated IHC and FISH in a large cohort of 1,005 invasive urothelial bladder cancers. They reported HER2 protein overexpression was 9.2% and *HER2* gene amplification was 5.1%. This is a lower frequency compared to previously reported figures in the literature ([@B4][@B13]). Lae et al. ([@B12]) pointed out that the major cause of this large variation was the technical heterogeneity in IHC and FISH assays in the earlier articles. The most recent article by cancer genomic atlas network also reported HER2 was a potential therapeutic target in 9% of urothelial carcinoma of the bladder ([@B26]). Therefore, the frequency of HER2 overexpression could be approximately 5%-10% in bladder cancer, which was suggested to be a potential candidate for target therapy.

As of now, there are only a few studies that investigated HER2 status in NMIBC, and they have yielded controversial results. Olsson et al. ([@B15]) reported HER2 protein was overexpressed in 12.4% of primary stage T1 bladder urothelial carcinomas, and there was no significant association between tumor HER2 status and prognosis including tumor progression and recurrence. Olsson et al. ([@B15]) used whole sections of pT1 tumors and analyzed HER2-IHC according to ASCO/CAP guidelines presented for breast cancers. On the other hand, a recent similar study had been conducted by Chen et al. ([@B14]) that investigated HER status of NMIBCs on TMA using IHC and FISH. They demonstrated that *HER2* gene amplification was 9% and correlated remarkably well with aggressive clinical outcome in high grade NMIBC, and suggested that HER2 status would be valuable for distinguishing patients with NMIBC who require diligent surveillance.

Our study concurred with the previous finding that *HER2* gene amplification is an independent predictor of tumor progression ([@B14]). *HER2* gene amplification was 2.8% in NMIBC, 5.3% of pT1 tumors, 5.9% in high grade NMIBC, and 7.1% of high grade pT1 tumors in current study. No amplification was observed in pTa tumors. This figure is a little lower than the statistics recorded in the previous reports ([@B12][@B14]), which was 5.1% in invasive bladder carcinomas ([@B12]), 4% in NMIBC, 9% in high grade NMIBC and 2.2% in pTa tumors ([@B14]). HER2 status of bladder cancer may differ among different populations. Ethnic or geographic differences in HER2 expression were documented in several literatures ([@B21]). Our results highlight a good concordance between HER2-IHC and *HER2*-SISH in NMIBC and *HER2*-SISH positive cases might be applicable for HER2 target therapy.

In the current study, HER2-IHC positive correlated well with recurrence or progression free survival, accounted for 4.3% of NMIBC, 6.6% of pT1 tumors, 8.8% of high grade NMIBC, and 8.9% of high grade pT1 tumors. Though tumor progression in NMIBC ranges widely from 1% to 45% ([@B1][@B2]), it was found to be 16.3% in the current study. An interesting finding was that all six HER2-IHC positive patients showed tumor progression. Although HER2-IHC positive cases take up a small percentage of NMIBC cases, we believe HER2-IHC positive patients should receive more aggressive surveillance and monitoring with respect to personalized medicine. HER2-IHC turned out to be more informative than *HER2*-SISH in our study. HER2-IHC is cheaper and technically more convenient than *HER2*-SISH, and could be used in a routine diagnostic practice if it is well calibrated at the laboratory.

We were uncertain whether the guideline for breast cancer and gastric cancer of HER2 expression would apply to urothelial carcinoma, especially since small 2 mm core of NMIBC on TMA. As mentioned in the materials and methods, scoring of HER2-IHC was grouped into four patterns; and several statistical analyses concluded that HER2 positive group with score 2+ and 3+ was statistically the most significant for survival analyses. Chen et al. ([@B14]) also ran a comparative test on 30%, 40%, and 50% cut off criteria of HER2 expression analysis and reported IHC and FISH results were in closest agreement when overexpression was defined as 50% of tumor cells showing immunoreactivity. Although they did not report the detail of HER2 IHC results with regard to tumor grade or stage, HER2 protein expression was 4.2% (50% criterion) in NMIBCs in [Table 2](#T2){ref-type="table"} of their article, which was the same with this study. In fact, one out of three cases with 2+ HER2-IHC showed gene amplification by *HER2*-SISH. Therefore, we classified HER2 score 2+ and 3+ as HER2-IHC positive group.

This study is also the first attempt to observe the changes in HER2 status using IHC and SISH depending on substage in NMIBC. Besides clinical and histopathological risk factors such as tumor grade, stage, concomitant CIS, multiplicity, tumor size, and previous recurrence rate, HER2 status and substage may be included as prognostic factors to the risk tables for bladder cancer ([@B2][@B6]). Granted, there are limitations in this study. The treatment has not been uniform for the NMIBC patients, whose therapy period ranged from 1998 to 2012. However, the tumor recurrence and progression data were from patients treated by a single institution. Therefore, HER2 assessment merits consideration in NMIBC diagnosis as well as prognostic and therapeutic management. Another limitation was the issue of tumor heterogeneity due to use of TMA tissue instead of whole sections of NMIBC. Intratumoral heterogeneity of HER2 expression was reported in 35% of invasive urothelial bladder carcinomas ([@B12]), but it was not investigated in earlier NMIBCs study using whole sections of tumor. In this study, the frequency of HER2-IHC positive (6.6% of pT1 tumors) was found to be lower than Olsson et al. ([@B15]) report (12.4% of pT1 tumors), which used whole tissue sections, but comparable to Chen et al. study ([@B14]), which used TMA tissue. On the other hand, Burandt et al. ([@B27]) identified homogeneously distributed HER2 overexpression/amplification in bladder cancers and demonstrated that tissue microarray based screening for therapeutic target genes represents a feasible approach suitable for routine application. Therefore, a future validation study with a set of reference samples of known HER2 status is necessary to attain the best protocol for HER2 status in NMIBC.

In conclusion, this study demonstrated that substaging, HER2 protein expression, and gene amplification are independent predictors of tumor progression in NMIBC. We recommend NMIBC should be tested for HER2 status as a predictive marker in practice, and therapeutic strategies of HER2 expression could be considered for the management of NMIBC.
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![HER2 immunohistochemistry (HER2-IHC). (A) 3+, moderate-to-strong complete membrane staining in all tumor area. (B) 2+, variable weak-to-moderate complete membrane staining in ≥ 50% of tumor area. (C) 1+, faint/barely partial membrane staining less than 50% of tumor area. (D) 0, no staining. (magnification × 200).](jkms-30-1068-g001){#F1}

![*HER2* gene amplification by dual-color silver in situ hybridization (*HER2*-SISH). *HER2*-SISH positive case (A) matched with HER2-IHC 3+ (B). (magnification: (A) × 1,000; (B) × 400).](jkms-30-1068-g002){#F2}

![Kaplan Meier analysis for recurrence free survival in NMIBC. Tumor size (A) and HER2-IHC positive (B) significantly correlated with recurrence-free survival.](jkms-30-1068-g003){#F3}

![Kaplan Meier analysis for progression free survival in NMIBC. Pathologic substage (A), tumor grade (B), HER2-IHC (C) and *HER2*-SISH (D) correlated with progression-free survival.](jkms-30-1068-g004){#F4}

###### Clinicopathologic characteristics of the 141 patients with NMIBC

![](jkms-30-1068-i001)

  Characteristics                   No. (%) of cases
  --------------------------------- -------------------
  Sex                               
   Male                             122 (86,5)
   Female                           19 (13.5)
  Age (mean, range, yr)             
   All                              68.9 (20-93)±13.6
   Male                             68.3 (20-93)±13.6
   Female                           72.7 (48-91)±13.5
  Follow up (months) for survival   
   Range                            3.9-187.9
   Mean S.D                         73.3±44.3
  Recurrence                        
   Absent                           73 (51.8)
   Present                          68 (48.2)
  Progression                       
   Absent                           118 (83.7)
   Present                          23 (16.3)
  Tumor size (n=187)                
   \<3 cm                           81 (57.4)
   ≥3 cm                            60 (42.6)
  Multifocality (n=195)             
   Single                           75 (53.2)
   Multiple                         66 (46.8)
  pT stage                          
   Ta                               65 (46.1)
   T1a                              50 (35.5)
   T1b                              9 (6.4)
   T1c                              17 (12.1)
  Tumor grade                       
   LMP                              14 (9.9)
   Low grade                        59 (41.8)
   High grade                       68 (48.2)
  Concomitant carcinoma in situ     
   Absent                           110 (78)
   Present                          31 (22)
  Lymphovascular invasion           
   Absent                           138 (97.9)
   Present                          3 (2.1)
  HER2 protein expression (IHC)     
   0                                127 (90.1)
   1                                8 (5.7)
   2                                3 (2.1)
   3                                3 (2.1)
  HER2 gene amplification (SISH)    
   Absent                           137 (97.2)
   Present                          4 (2.8)

NMIBC, nonmuscle-invasive bladder cancer; LMP, low malignant potential; IHC, immunohistochemistry; SISH, Silver In-Situ Hybridization.

###### Comparison of substage and other clinicopathologic parameters in NMIBC

![](jkms-30-1068-i002)

  Parameters                       pTa         pT1a        pT1b       pT1c        *P* value
  -------------------------------- ----------- ----------- ---------- ----------- -----------
  Total (n = 141), (%)             65 (46.1)   50 (35.5)   9 (6.4)    17 (12.1)   
  Tumor grade                                                                     \< 0.001
   LMP                             14 (21.5)   0 (0)       0 (0)      0 (0)       
   Low grade                       39 (60))    15 (30)     1 (11.1)   4 (23.5)    
   High grade                      12 (18.5)   35 (70)     8 (88.9)   13 (76.5)   
  Multifocality                                                                   0.084
   Single                          39 (60)     28 (56)     3 (33.3)   5 (29.4)    
   Multiple                        26 (40)     22 (44)     6 (66.7)   12 (70.6)   
  Tumor size                                                                      0.393
   \<3                             41 (63.1)   24 (48)     6 (66.7)   10 (58.8)   
   ≥3                              24 (36.9)   26 (52)     3 (33.3)   7 (41.2)    
  Concomitant CIS                                                                 0.005
   Absent                          59 (90.8)   33 (66)     5 (55.6)   13 (76.5)   
   Present                         6 (9.2)     17 (34)     4 (44.4)   4 (23.5)    
  LVI                                                                             0.109
   Absent                          65 (100)    49 (98)     8 (88.9)   16 (94.1)   
   Present                         0 (0)       1 (2)       1 (11.1)   1 (5.9)     
  HER2 protein expression (IHC)                                                   0.038
   Negative                        64 (98.5)   48 (96)     7 (77.8)   16 (94.1)   
   Positive                        1 (1.5)     2 (4)       2 (22.2)   1 (5.9)     
  HER2 gene amplification (SISH)                                                  0.002
   Absent                          65 (100)    49 (98)     7 (77.8)   16 (94.1)   
   Present                         0 (0)       1 (2)       2 (22.2)   1 (5.9)     
  Recurrence                                                                      0.993
   Absent                          33 (50.8)   26 (52)     5 (55.6)   9 (51.8)    
   Present                         32 (49.2)   24 (48)     4 (44.4)   8 (47.1)    
  Progression                                                                     \< 0.001
   Absent                          62 (95.4)   43 (86)     4 (44.4)   9 (52.9)    
   Present                         3 (4.6)     7 (14)      5 (55.6)   8 (47.1)    

LMP, low malignant potential; CIS, carcinoma in situ; LVI, lymphovascular invasion; NMIBC, nonmuscle invasive bladder cancer; IHC, immunohistochemistry; SISH, silver in-situ hybridization.

###### Comparison of tumor grade and HER status with other clinicopathologic parameters in NMIBC

![](jkms-30-1068-i003)

  Parameters Total (n=141)   Tumor grade   HER2 IHC    HER2 SISH                                         
  -------------------------- ------------- ----------- ------------ ------------ ---------- ------------ ---------
  Tumor grade                                                                                            
   LMP                       14 (10.4)     0 (0)       14 (10.2)    0                                    
   Low                       59 (43.7)     0 (0)       59 (43.1)    0 (0)                                
   High                      62 (45.9)     6 (100)     64 (46.7)    4 (100)                              
  Multifocality                                                                                          
   Single                    9 (64.3)      37 (62.7)   29 (42.6)    73 (54.1)    2 (33.3)   73 (53.3)    2 (50)
   Multiple                  5 (35.7)      22 (37.3)   39 (57.4)    62 (45.9)    4 (66.7)   64 (46.7)    2 (50)
  Tumor size                                                                                             
   \<3                       11 (78.6)     32 (54.2)   38 (55.9)    78 (57.8)    3 (50.0)   79 (57.7)    2 (50)
   ≥3                        3 (21.4)      27 (45.8)   30 (44.1)    57 (42.2)    3 (50.0)   58 (42.3)    2 (50)
  Concomitant CIS                                                                                        
   Absent                    14 (100)      54 (91.5)   42 (61.8)    106 (78.5)   4 (66.7)   108 (77.4)   4 (100)
   Present                   0 (0)         5 (8.5)     26 (38.2)    29 (21.5)    2 (33.3)   31 (22.6)    0 (0)
  LVI                                                                                                    
   Absent                    14 (100)      58 (98.3)   66 (97.1)    134 (99.3)   4 (66.7)   136 (99.3)   2 (50)
   Present                   0 (0)         1 (1.7)     2 (2.9)      1 (0.7)      2 (33.3)   1 (0.7)      2 (50)
  HER2 IHC                                                                                               
   Negative                  14 (100)      59 (100)    62 (91.2)    135 (98.5)   0 (0)                   
   Positive                  0 (0)         0 (0)       6 (8.8)      2 (1.5)      4 (100)                 
  HER2 SISH                                                                                              
   Absent                    14 (100)      59 (100)    64 (94.1)    135 (100)    2 (33.3)                
   Present                   0 (0)         0 (0)       4 (5.9)      0 (0)        4 (66.7)                
  Recurrence                                                                                             
   Absent                    10 (71.4)     24 (40.7)   39 (57.4)    71 (52.6)    2 (33.3)   71 (51.8)    2 (50)
   Present                   4 (28.6)      36 (59.3)   29 (42.6)    64 (47.4)    4 (66.7)   66 (48.2)    2 (50)
  Progression                                                                                            
   Absent                    14 (100)      55 (93.2)   49 (72.1 )   118 (87.4)   0 (0)      118 (86.1)   0 (0)
   Present                   0 (0)         4 (6.8)     19 (27.9)    17 (12.6)    6 (100)    19 (13.9)    4 (100)

Bold, *P*\<0.005. LMP, low malignant potential; CIS, carcinoma in situ; LVI, lymphovascular invasion; NMIBC, nonmuscle invasive bladder cancer; IHC, immunohistochemistry; SISH, silver in-situ hybridization.

###### Univariate and multivariate analyses for recurrence and progression-free survival

![](jkms-30-1068-i004)

  Variables       Recurrence free survival   Progression free survival                                             
  --------------- -------------------------- --------------------------- ------- ------- ------------------------- ----------
  Substage        0.704                      N/A                         N/A     0       1.999 (1.355-2.949)       \< 0.001
  Tumor size      0.042                      1.595 (0.989-2.572)         0.055   0.317   N/A                       N/A
  Multifocality   0.22                       N/A                         N/A     0.041   1.360 (0.490-3.775)       0.555
  Tumor grade     0.168                      N/A                         N/A     0       2.009 (0.660-6.114)       0.219
  CIS             0.569                      N/A                         N/A     0.95    N/A                       N/A
  LVI             0.616                      N/A                         N/A     0       1.861 (0.177-19.611)      0.605
  HER2 IHC        0                          3.459 (1.223-9.781)         0.019   0       84.642 (11.661-614.393)   \< 0.001
  HER2 SISH       0.195                      N/A                         N/A     0       0.086 (0.009-0.800)       0.031

Only risk factors with *P* values\<0.05 were included in the multivariate analysis. IHC, immunohistochemistry; SISH, silver in-situ hybridization; CI, confidence interval; N/A, not available.
